4ZU0 Stock Overview
A clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Biora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$16.50 |
| 52 Week Low | US$4.30 |
| Beta | 1.12 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -60.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4ZU0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 3.4% |
| 1Y | -60.4% | -14.9% | 15.0% |
Return vs Industry: 4ZU0 underperformed the German Biotechs industry which returned -13% over the past year.
Return vs Market: 4ZU0 underperformed the German Market which returned 6.8% over the past year.
Price Volatility
| 4ZU0 volatility | |
|---|---|
| 4ZU0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4ZU0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4ZU0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 58 | Adi Mohanty | www.bioratherapeutics.com |
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. Fundamentals Summary
| 4ZU0 fundamental statistics | |
|---|---|
| Market cap | €2.00m |
| Earnings (TTM) | -€34.18m |
| Revenue (TTM) | €857.03k |
2.3x
P/S Ratio-0.1x
P/E RatioIs 4ZU0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4ZU0 income statement (TTM) | |
|---|---|
| Revenue | US$892.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$892.00k |
| Other Expenses | US$36.47m |
| Earnings | -US$35.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.04 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,988.12% |
| Debt/Equity Ratio | -36.9% |
How did 4ZU0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 01:46 |
| End of Day Share Price | 2024/09/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biora Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Poon Mah | Piper Sandler Companies |
| Andrew Cooper | Raymond James & Associates |